FDA Probe Could Grow To Encompass Fresenius Empire

Law360, New York (June 15, 2012, 8:52 PM EDT) -- The U.S. Food and Drug Administration confirmed Friday it was investigating Fresenius Medical Care North America's decision to alert company-affiliated physicians of cardiac risks linked to a dialysis treatment months before other health professionals, a step that could lead to litigation and kick off regulatory scrutiny of much larger pieces of the company's medical device empire.

Fresenius circulated an internal memorandum to medical directors and physicians at its dialysis centers in November warning of "troubling findings" associated with its Granuflo product. Improper use of the product...
To view the full article, register now.